Showing 3451-3460 of 5773 results for "".
- New Data on Two Nicox’s Assets, NCX 470 and NCX 1728, Presented at ARVO 2023https://modernod.com/news/new-data-on-two-nicoxs-assets-ncx-470-and-ncx-1728-presented-at-arvo-2023/2481567/Nicox announced that studies highlighting nonclinical data on NCX 470 and NCX 1728 have been presented at the Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting 2023 being held April 23-27, 2023 in New Orleans. Poster title: NCX 470, a nitric oxide (NO)-donating&
- Genentech: New Vabysmo Data Suggest Greater Retinal Drying vs. Aflibercept in Wet AMD and DMEhttps://modernod.com/news/genentech-new-vabysmo-data-suggest-greater-retinal-drying-vs-aflibercept-in-wet-amd-and-dme/2481564/Genentech announced that post-hoc data indicate treatment with Vabysmo (faricimab-svoa) led to greater and faster drying of retinal fluid with fewer injections compared to aflibercept in wet age-related macular degeneration (AMD). In diabetic macular edema (DME), post-hoc data suggest V
- eSight Names New Senior Leadershiphttps://modernod.com/news/esight-names-new-senior-leadership/2481562/eSight announced the selection of John Tushar as the new Chairman of the Board; Aaron Tutwiler as the new CEO; and Roland Mattern as Director of Sales and Marketing. In these new roles, the three senior leaders will drive forward the execution of the company’s long-term
- Zeiss Receives FDA Approval of the CT Lucia 621P Monofocal IOLhttps://modernod.com/news/zeiss-receives-fda-approval-of-the-ct-lucia-621p-monofocal-iol/2481561/Zeiss announced that the FDA has approved the CT Lucia 621P monofocal IOL, an aspheric, monofocal, single-piece C-loop IOL. The IOL features the patented Zeiss Optic (ZO) Asphericity Concept, which is designed to compensate for a wide range of spherical aberrations and at
- Ciliatech Raises Money to Advance Development of Disruptive Glaucoma Implanthttps://modernod.com/news/ciliatech-raises-money-to-advance-development-of-disruptive-glaucoma-implant/2481560/Ciliatech announced it has raised €3.5M (about $4 million) to advance the company's glaucoma implant, CID (Cilio-scleral Inter-positioning Device), a technology that aims to disrupt traditional approaches in glaucoma surgery. Ciliatech says CID differs from other glau
- GenSight Biologics Withdraws its EMA Application for Lumevoqhttps://modernod.com/news/gensight-biologics-withdraws-its-ema-application-for-lumevoq/2481559/GenSight Biologics announced that it has decided to withdraw an application with the European Medicines Agency (EMA) seeking approval of Lumevoq (lenadogene nolparvovec) in patients with Leber hereditary optic neuropathy (LHON). The moves comes after the Committee for Advanced Therapies (CAT
- Lenstar Myopia Now Includes New AMMC Framework by Prof. Dr. Hakan Kaymakhttps://modernod.com/news/lenstar-myopia-now-includes-new-ammc-framework-by-prof-dr-hakan-kaymak/2481558/Haag-Streit has announced that the Lenstar Myopia now includes the new AMMC framework by Prof. Dr. Hakan Kaymak. The new Age-Matched Myopia Control (AMMC) framework is designed to provide diagnostic support based on the eye’s axial growth for myopia m
- New Trefoil Therapeutics’ Data Presented at ARVO Demonstrate that TTHX1114 Controls Edema in At-Risk Patients Undergoing Cataract Surgeryhttps://modernod.com/news/new-trefoil-therapeutics-data-presented-at-arvo-demonstrate-that-tthx1114-controls-edema-in-at-risk-patients-undergoing-cataract-surgery/2481556/Trefoil Therapeutics announced a series of data presentations demonstrating the potential use of TTHX1114 to protect endothelial cells at the Association for Research in Vision and Ophthalmology (ARVO) annual meeting in New Orleans. The company also announced the completion of the phase 1 epithel
- Johnson & Johnson Vision Showcases 30 New Sets of Scientific Data on Myopia, Refractive Technologies, IOLs and More at ARVOhttps://modernod.com/news/johnson-johnson-vision-showcases-30-new-sets-of-scientific-data-on-myopia-refractive-technologies-iols-and-more-at-arvo/2481554/Johnson & Johnson Vision announced that it is presenting 30 sets of research spanning the spectrum of eye health including myopia, refractive technology, sphere, intraocular lenses, astigmatism, consumer eye health, and vision science at the Association for Research in Vision and Ophthalmolog
- Apellis Presents Phase 3 Functional Analyses of Syfovre for Geographic Atrophyhttps://modernod.com/news/apellis-presents-phase-3-functional-analyses-of-syfovre-for-geographic-atrophy/2481553/Apellis Pharmaceuticals announced post hoc analyses from the 24-month, phase 3 OAKS and DERBY studies evaluating Syfovre (pegcetacoplan injection) for the treatment of geographic atrophy (GA) secondary to age-related macular degeneration (AMD). The analyses were reported during oral presenta